通过liquiritigenin和结构基础抑制AKR1Cs
Huan Liu1, Ziqing Yao1, Mingna Sun1
1Key Laboratory of Molecular Target & Clinical Pharmacology and the State Key Laboratory of Respiratory Disease, School of Pharmaceutical Sciences & the Fifth Affiliated Hospital, Guangzhou Medical University, Guangzhou, 511436, China.
甘中的一种化合物Liquiritigenin (LQ) 抑制了在荷尔蒙依赖癌症中至关重要的AKR1C酶. 了解这种机制有助于开发新的前列腺癌和乳腺癌抗瘤疗法.
科学领域:
- 生物化学 生物化学
- 分子生物学分子生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 从甘草中提取的液化基因因 (LQ) 具有抗瘤特性.
- 通过LQ抑制瘤生长的精确机制仍然不完全理解.
- AKR1C酶 (AKR1C1-3) 与前列腺癌和乳腺癌以及耐药性有关.
研究的目的:
- 为了研究液化原蛋白 (LQ) 和相关的黄对AKR1C酶的酶抑制.
- 通过结晶学研究阐明LQ与AKR1C3相互作用的结构基础.
- 了解LQ抑制对AKR1C酶的异型选择性.
主要方法:
- 对LQ和六种弗拉万类型进行了酶抑制试验,针对AKR1C1,AKR1C2和AKR1C3.3.
- 使用X射线结晶学来确定与AKR1C3.3结合的LQ的结构.
- 进行了与AKR1C1和AKR1C3复合的LQ的整合分析.
主要成果:
- LQ证明了对AKR1C酶的酶抑制.
- 结晶学数据揭示了LQ与AKR1C3活性位点的互补性,该活性位点由键稳定,并且具有独特的结构.
- 在与AKR1C1和AKR1C3结合时,LQ的形态变化解释了其缺少异形选择性.
结论:
- 这项研究提供了结构性洞察力,了解liquiritigenin对AKR1C酶的抑制.
- 这些发现有助于了解LQ在荷尔蒙依赖癌症中的抗瘤作用.
- 结果可以指导用于癌症治疗的新型选择性AKR1C抑制剂的合理设计.
更多相关视频
08:49Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries
Published on: January 22, 2019
10:46A Calcium Bioluminescence Assay for Functional Analysis of Mosquito Aedes aegypti and Tick Rhipicephalus microplus G Protein-coupled Receptors
Published on: April 20, 2011
相关概念视频
Enzyme Inhibition
Eukaryotic Transcription Inhibitors
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
Indirect-Acting Cholinergic Agonists: Mechanism of Action
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex,...
Feedback Inhibition
Indirect-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
Ligand-Gated Ion Channel Receptor: Gating Mechanism
